A measured research overview of the HCG peptide: its glycoprotein structure, LHCGR mechanism and cAMP signalling bias, the hypogonadotropic hypogonadism and ovulation-trigger data, and why the approved label rejects the obesity claim.
Human chorionic gonadotropin (HCG) occupies an unusual position in the research catalogue: decades of controlled human trial data behind a narrow set of indications, and an equally long record of marketing claims the same evidence contradicts.
A framing note first. HCG peptide is a common search term, but the label is imprecise: HCG is a heterodimeric glycoprotein hormone — two non-covalently associated, heavily glycosylated subunits produced by the placental syncytiotrophoblast — not a short synthetic chain like BPC-157 or Semax. The distinction drives everything downstream: how it is manufactured, why it is measured in international units rather than micrograms, and why it persists in circulation far longer than its closest endogenous relative.
HCG shares a common α subunit with luteinizing hormone (LH), FSH, and TSH; specificity comes from the β subunit. β-HCG and β-LH share substantial sequence homology, but β-HCG carries an additional carboxy-terminal peptide (CTP) extension — approximately residues 113–145 — that LH lacks, plus several additional glycosylation sites.
That extension is the most consequential structural difference. Reviews of gonadotropin pharmacology attribute HCG's markedly longer circulating half-life — on the order of a day or more, against roughly 30–60 minutes for LH — primarily to the CTP's O-linked sugars, which slow metabolic clearance, rather than to the sequence itself. The CTP is now the basis of engineered long-acting gonadotropins.
HCG and LH act on the same receptor — the luteinizing hormone/choriogonadotropin receptor (LHCGR), a seven-transmembrane GPCR with a large extracellular binding domain. Activated LHCGR couples to Gαs, driving adenylyl cyclase, cAMP, and protein kinase A; at high hormone and receptor densities it also recruits Gαq and calcium signalling. In males, that cascade in Leydig cells drives intratesticular testosterone synthesis; in females, oocyte maturation, ovulation, and luteal support.
A shared receptor does not mean identical behaviour. Work identifying the receptor residues that discriminate HCG- from LH-specific signalling found HCG more potent than LH at inducing cAMP (lower EC50), while LH is more potent at phosphorylating ERK1/2 and AKT. HCG is biased toward the steroidogenic cAMP/PKA arm — which is why it is not simply "LH with a longer half-life."
Hypogonadotropic hypogonadism. HCG's strongest dataset. A systematic review and meta-analysis of gonadotropins for pubertal induction in males with hypogonadotropic hypogonadism (European Journal of Endocrinology, 2024) found HCG alone induced spermatogenesis in a pooled 40% of patients (95% CI 25–56%), while HCG combined with FSH reached 86% (95% CI 82–91%). Weekly dosages ranged from 625 to 15,000 IU (median ~4,500 IU/week); the median treatment course ran 18 months. Two honest caveats: heterogeneity was high (I² = 83% for the HCG-alone estimate), and achieving any spermatogenesis is a materially lower bar than sperm output sufficient for natural conception.
Cryptorchidism. Here the data cut against use. Meta-analyses of randomised, blinded HCG trials report testicular descent in roughly 19–21% of cases, against 4–6% for placebo and >70% for orchiopexy; reviews conclude hormonal therapy cannot be broadly recommended. An approved indication whose own trials argue against it.
Ovulation trigger. The long half-life makes HCG a durable surrogate for the endogenous LH surge — the basis of the standard 5,000–10,000 IU trigger after follicular stimulation. It is also the direct trigger of ovarian hyperstimulation syndrome, the most serious complication of controlled ovarian stimulation, which is why lower trigger doses are used where OHSS risk is elevated.
Testosterone-replacement adjunct. Hsieh et al. (2013, Journal of Urology) reported that low-dose HCG — 500 IU intramuscularly every other day — alongside testosterone replacement preserved semen parameters across 26 men, none becoming azoospermic. Weigh the design before the finding: 26 patients, retrospective, no control arm.
No honest overview omits this. FDA-approved labelling for chorionic gonadotropin states, in capitals, that HCG "HAS NOT BEEN DEMONSTRATED TO BE EFFECTIVE ADJUNCTIVE THERAPY IN THE TREATMENT OF OBESITY," and that it "HAS NO KNOWN EFFECT ON FAT MOBILIZATION, APPETITE OR SENSE OF HUNGER, OR BODY FAT DISTRIBUTION." The label further notes no substantial evidence that HCG increases weight loss beyond caloric restriction alone. The FDA has separately acted against "homeopathic" HCG weight-loss products as illegal and unapproved.
Outcomes reported for the "HCG diet" track the accompanying severe caloric restriction, not the hormone — and that restriction carries its own documented risks. HCG's mechanism bears no relationship to the incretin compounds; the GLP-1 receptor agonists are a separate pharmacology entirely.
HCG acts at the bottom of the hypothalamic–pituitary–gonadal axis, at the gonadal receptor itself — a different intervention point from kisspeptin, which acts upstream of GnRH and depends on an intact downstream axis to do anything. HCG bypasses the hypothalamus and pituitary entirely, which is why it retains activity where upstream signalling has failed. FSH is complementary rather than comparable: the meta-analytic gap between HCG alone and HCG+FSH is the clearest evidence the two gonadotropins do different jobs.
Unusually here, the constraint is not absent data — it is that the data are specific. Well-characterised pharmacology and decades of trials sit alongside clearly delineated boundaries where those trials return null or negative results. Extrapolating from the fertility literature to body composition, athletic performance, or general "hormone optimisation" is not supported by any source cited above. Preparation matters too: urinary-derived HCG and recombinant choriogonadotropin alfa differ in purity and batch-to-batch consistency. Because HCG is standardised in international units rather than by mass, its reconstitution arithmetic differs from the mg/mcg conventions used elsewhere — see dosing math and reconstitution 101.
For sport-science contexts: WADA prohibits chorionic gonadotropin at all times in male athletes, listed under S2 among testosterone-stimulating peptides.
Is HCG actually a peptide? Not strictly. HCG is a heterodimeric glycoprotein hormone of two glycosylated subunits — considerably larger and more heavily modified than the short synthetic chains usually meant by "peptide." It is catalogued alongside peptides by convention rather than chemistry.
How does HCG differ from LH if they share a receptor? Structurally, β-HCG carries a carboxy-terminal peptide extension and extra glycosylation that LH lacks, giving it a half-life measured in tens of hours rather than tens of minutes. Pharmacologically, HCG is biased toward cAMP/PKA signalling while LH more strongly activates ERK1/2 and AKT — so the two are not interchangeable at the receptor.
What is the strongest evidence base for HCG? Gonadotropin therapy in hypogonadotropic hypogonadism. Pooled meta-analytic data show spermatogenesis induction in roughly 40% with HCG alone versus 86% with HCG plus FSH, over courses with a median of about 18 months. Heterogeneity across the underlying studies was high.
Does the research support HCG for weight loss? No. FDA-approved labelling states explicitly that HCG has not been shown to be effective adjunctive therapy for obesity and has no known effect on fat mobilisation, appetite, or body-fat distribution. Weight change on the "HCG diet" tracks the severe caloric restriction, not the hormone.
